FDA Opens a 510(k) Path for Cancer Gene Panels

FDA's 6 October 2026 Federal Register carried a final order that formally classifies high-throughput DNA sequencing for hereditary cancer predisposition assessment as a Class II generic device type. The filing does not authorize a new product; it codifies the regulatory status of a category FDA created three years ago for a single device, and in doing so opens a 510(k) pathway for anyone who builds a substantially equivalent panel.

Why a three-year-old approval is back in the Federal Register

De Novo authorization and classification are two separate steps, and sponsors sometimes confuse them. A De Novo grant lets FDA authorize a novel, low-to-moderate-risk device that has no existing predicate, but it authorizes that one device for that one applicant. Nothing obligates FDA to publish a generic classification regulation afterward, and nothing requires it to happen quickly — Invitae's panel cleared in September 2023, and the classification codifying its device type did not appear until this month. Until that regulation exists, a second company building a similar hereditary-cancer sequencing panel has no predicate to cite and would, in principle, need to run its own De Novo request. The 6 October order closes that gap.

What changes for competitors

With the generic type now on the books at 21 CFR 866.6095, a company whose high-throughput hereditary-cancer sequencing panel is substantially equivalent to the classified type can submit a 510(k) instead of a De Novo petition. That is normally a faster, cheaper review: a 510(k) turns on comparison to a predicate and compliance with the type's special controls, rather than a first-principles risk-benefit case for an entirely new category. It does not mean a competing panel skips scrutiny — the special controls FDA attaches to a Class II generic type exist precisely to hold follow-on devices to the analytical and clinical validation standard the De Novo review established. Sponsors should read the special controls in the order itself before assuming any specific gene panel, sample size, or accuracy threshold travels automatically from Invitae's authorization to their own.

• What happened: FDA classified high-throughput hereditary-cancer DNA sequencing test systems as Class II, three years after authorizing the first such device.
• What it unlocks: a 510(k) pathway for substantially equivalent panels, in place of a fresh De Novo review for each new entrant.
• What is unchanged: Invitae's underlying authorization and its intended-use limits — prescription use, not for screening or prenatal testing, not a stand-alone diagnostic.
• What to check: the special controls text in FR Doc. 2026-20443 itself before scoping a 510(k) submission against this new predicate.

Frequently asked questions

What did FDA publish on 6 October 2026?

A final order, "Medical Devices; Immunology and Microbiology Devices; Classification of the High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System," FR Doc. 2026-20443, 91 FR 63487-63491. It establishes the device type as Class II under 21 CFR 866.6095, with product code QVU.

What device created this classification?

Invitae Corporation's Common Hereditary Cancers Panel, authorized through FDA's De Novo pathway on 29 September 2023 as the first marketing authorization for a high-throughput DNA sequencing test to assess predisposition across dozens of cancer types. FDA said at the time the 47-gene panel was validated on more than 9,000 samples with at least 99.0 percent accuracy.

Why does a classification order matter if the device is already on the market?

A De Novo grant authorizes one device and, until a classification regulation follows, gives FDA no established generic type for a competitor to cite. Publishing the Class II regulation creates that generic type and predicate, so a sponsor with a substantially equivalent panel can now file a 510(k) rather than running its own De Novo review from scratch.

What is the test not cleared for?

Per FDA's original authorization, the panel is not intended for population screening, prenatal testing, or as a stand-alone diagnostic; it is prescription-use only and intended to aid qualified health care professionals, in conjunction with professional guidelines and other clinical information, in assessing a patient's predisposition to hereditary cancer.